FindTrial
Sign In

Oral tofacitinib in the treatment of nail lichen planus

Efficacy of oral tofacitinib in the treatment of nail lichen planus: a pilot clinical trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076876
Enrollment
20
Registered
2024-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L608- Other nail disorders

Interventions

Intervention1: Tofacitinib: Oral tofacitinib 5 mg twice daily for 6 months Control Intervention1: Not applicable: Not applicable

Sponsors

All India Institute Of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with nail lichen planus involving more than 3 nails with or without skin, hair and mucosa involvement

Exclusion criteria

Exclusion criteria: 1. Anonychia of all 20 nails 2. Pregnant and lactating females 3. Patients with known contra-indications to oral tofacitinib 4. Patients with known cardiovascular disease or venous thromboembolism 5. Patients on topical treatment for last 2 weeks, systemic treatment for last 4 weeks 6. Current or history of malignancy

Design outcomes

Primary

MeasureTime frame
Proportion of patients with clinical improvement of nail lichen planus after treatmentTimepoint: 3 months and 6 months—

Secondary

MeasureTime frame
1 Change in mean NALSI after treatment 2. Change in mean DLQI after treatment Timepoint: 3 months and 6 months—

Countries

India

Contacts

Public ContactDr Somesh Gupta

All India Institute Of Medical Sciences

someshgupta@hotmail.com9868899120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026